Table 3 Clinical, laboratory, and radiologic features at first examination
From: COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
COVID-19 patients, N pts/N evaluable (%) | RNA-positive subgroup, N pts/N evaluable (%) | |
|---|---|---|
Clinical examination | ||
Fever (≥ 38.0 °C) | 27/59 (46%) | 21/41 (51%) |
Cough | 22/59 (37%) | 18/41 (44%) |
Dyspnea | 17/59 (29%) | 10/41 (24%) |
Decreased saturation (< 96%) | 7/59 (12%) | 5/41 (12%) |
GI disorders | 6/59 (10%) | 5/41 (12%) |
Headache | 3/59 (5%) | 3/41 (7%) |
Anosmia/dysgeusia | 5/59 (8%) | 4/41 (10%) |
Possible nosocomial infection | 9/59 (15%) | 8/41 (20%) |
Laboratory parameters | ||
Neutrophil count: mean (IQR) (G/L) | 4.0 (2.0–5.1), N = 49 | 4.3 (2.0–5.0), N = 31 |
Lymphocyte count: mean (IQR) (G/L) | 1.5 (0.8–1.9), N = 49 | 1.5 (1.3–3.9), N = 31 |
LDH > ULN | 11/12 (92%) | 4/4 (100%) |
CT scan available for central review | ||
Extent of lesions (% of lung volume) | ||
No lesion | 2/28 (7%) | 2/14 (14%) |
< 10% | 11/28 (39%) | 2/14 (14%) |
10–25% | 12/28 (42%) | 8/14 (57%) |
26–50% | 2/28 (7%) | 1/14 (7%) |
51–75% | 1/28 (4%) | 1/14 (7%) |
> 75% | 0/28 (0%) | 0/14 (0%) |
Predominant type of lesion | ||
No lesion | 2/28 (7%) | 2/14 (14%) |
Ground-glass opacities | 14/28 (50%) | 7/14 (50%) |
Crazy paving | 4/28 (14%) | 1/14 (7%) |
Focal consolidation | 7/28 (25%) | 3/14 (22%) |
Linear consolidation | 1/28 (0%) | 1/14 (7%) |
Loco-regional radiation therapy | ||
No radiation therapy | 9/28 (32%) | 8/14 (57%) |
No sequela (0%) | 8/28 (29%) | 4/14 (29%) |
Sequela extent: 1–10% of lung volume | 9/28 (32%) | 2/14 (14%) |
Sequela extent: 11–25% of lung volume | 2/28 (7%) | 0/14 (0%) |
Sequela extent: > 25% of lung volume | 0/28 (0%) | 0/14 (0%) |